Stockreport

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee [Yahoo! Fin...

G1 Therapeutics, Inc.  (GTHX) 
Last g1 therapeutics, inc. earnings: 2/26 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: g1therapeutics.com/pages/investors/investors.htm
PDF announced that the independent Data Monitoring Committee (DMC) recommended continuation of the pivotal Phase 3 trial (PRESERVE 2), evaluating trilaciclib in combination [Read more]